May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Long-Term Results of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion
Author Affiliations & Notes
  • H.-W. Kwak
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • E.-S. Kim
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • S.-W. Lee
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • S.-Y. Yu
    Ophthalmology, Kyung Hee University, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  H. Kwak, None; E. Kim, None; S. Lee, None; S. Yu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2714. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.-W. Kwak, E.-S. Kim, S.-W. Lee, S.-Y. Yu; Long-Term Results of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2714. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long-term clinical efficacy of intravitreal bevacizumab in patients with macular edema (ME) secondary to retinal vein obstruction (RVO).

Methods: : Sixteen eyes of 16 patients with decreased visual acuity due to ME with RVO were included. Patients received 3 intravitreal injections of 1.25mg (0.05ml) bevacizumab (Avastin®) at intervals of 6 weeks each. All patients completed 1 year of follow-up. The patients underwent additional bevacizumab injection, if ME was increased in optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) with ETDRS chart and macular thickness using OCT were measured at baseline and follow-up visits.

Results: : The mean duration of follow-up was 12.4±1.1 months. The mean baseline BCVA (log MAR) was 0.75±0.32 and the final BCVA (log MAR) was 0.42±0.25, a difference that was statistically significant (p<0.05). Mean macular thickness at baseline by OCT was 588.5±301.0µm and decreased to a mean of 191.8±112.0µm at the end of the follow-up (p<0.05). During follow-up, the mean number of injections was 3.31 and there were no systemic side effects observed associated with bevacizumab and no endophthalmitis or other local side effects occurred.

Conclusions: : Intravitreal bevacizumab was well tolerated in all patients and effective for improving visual acuity and reducing macular edema for 1 year with 3.31 injections.

Keywords: vascular occlusion/vascular occlusive disease • vascular endothelial growth factor • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×